The Latest Breaking News from Chemotherapy

A Teen Gamer's Red Hand Patches Looked Worrying During Leukemia Treatment, Until Doctors Checked His Controller Grip

Red patches on a 19-year-old's hands during leukemia treatment were bleeding from game controller friction plus chemotherapy-lowered platelets.

Medical Daily · 6h ago

Five Radiation Sessions Before Pancreatic Cancer Surgery Preserved Physical Function, but Survival Was Numerically Lower in Small Trial

Five radiation sessions before pancreatic cancer surgery eased fatigue in a trial, but survival was lower and not yet established. What patients should ask.

Medical Daily · 7h ago

Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short

Merck and Daiichi pulled their bid for accelerated approval of I-DXd in small-cell lung cancer after FDA feedback. What patients should ask now.

Medical Daily · 14h ago

Texas A&M Scientists Map a Stress Shield That May Help Liver Cancer Cells Survive Chemotherapy in Lab Tests

Texas A&M lab work links the URM1 stress pathway to chemotherapy survival in liver cancer cells. The findings are early and untested in patients.

Medical Daily · Sep 25

What Every Woman Wears to a Hospital Waiting Room and What That Outfit Is Really Doing

You Open the Wardrobe KnowingYou already know what the day holds before you reach for anything. The hospital appointment is at ten. Someone you love is in a bed somewhere in that building, or you are the one going in, or you are the one waiting for news that will…

Times Life · Sep 24

Pancreatic Cancer Pill Daraxonrasib Gets FDA Breakthrough Status for Untreated Metastatic Disease When Paired with Standard Chemotherapy

The FDA gave daraxonrasib breakthrough status with gemcitabine and nab-paclitaxel for untreated metastatic pancreatic cancer. The combination is not yet approved.

Medical Daily · Sep 17

Ivonescimab Topped Keytruda on Median Lung Cancer Survival by Eight Months in China but Lacks U.S. Approval

Ivonescimab beat Keytruda on survival in a China-only lung cancer trial, but the drug is not approved in the U.S. Here is what patients should know.

Medical Daily · Sep 17

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.

Medical Daily · Sep 17

12-year-old finds 14,000 Kirstys across 50 countries, raises £100,000

Kirsty Waugh from Tunbridge Wells has turned her own name into a worldwide fundraising mission while continuing treatment for a brain tumour. This 12-year-old girl has tracked down 14,000 people called Kirsty across 50 countries, bringing them together through an online map and a growing collection of photographs. The campaign…

The Times of India · Sep 17

Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending

Gotistobart reached 18.5 months median survival versus 10.0 months for chemotherapy in 87 previously treated squamous lung cancer patients. Pivotal data pending.

Medical Daily · Sep 14